Wall Street may be underestimating monday.com (NASDAQ: MNDY). Despite stronger-than-expected Q3 earnings, weaker Q4 guidance and slowing revenue... ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Good Morning
U.S. stocks remained volatile Monday, with the Dow recording its third 1,000-point swing in four trading days. AMD shares rose after the company said its fifth-generation EPYC processors would power Google Cloud’s TPU 8tx systems, and Wall Street upgraded the stock.
Earnings drove several notable moves. Take-Two Interactive shares climbed after its results and an update on GTA 6 preorders, while Rocket Lab fell about 4% in after-hours trading. Digital Turbine shares also dropped in extended trading following its quarterly results.
Elsewhere, AAON reported record third-quarter sales of $707.4 million, up 84.1% from a year earlier. The Trade Desk reported revenue of $736 million, down 0.5%, and expanded its share repurchase program. Surgery Partners shares jumped as a Bon Secours affiliate increased its buyout offer.
Featured: Today's stock pick is on me (Ad)
|
Technology
|
|
|
Wall Street may be underestimating monday.com (NASDAQ: MNDY). Despite stronger-than-expected Q3 earnings, weaker Q4 guidance and slowing revenue growth have weighed on the stock. But improving profitability, substantial share repurchases, and new AI initiatives could provide the foundation for a lo...
Read the Full Story
|
|
|
|
Finance
|
|
|
As the AI sell-off continues to challenge many of the gains that the tech sector made throughout the year, investors may be looking for opportunities outside of that space—and even beyond large- or mega-cap names entirely. Top mid-cap growth names like Affirm Holdings Inc. (NASDAQ: AFRM) and DraftK...
Read the Full Story
|
|
Utilities
|
|
|
Investors wondering whether OKLO (NASDAQ: OKLO) has changed its narrative enough to trigger an explosive stock price increase can rest easy knowing it has. The questions, however, are whether it will keep rebounding, how high the stock can get, and if it will stay at loftier levels—because it may n...
Read the Full Story
|
|
From Our Partners
|
|
|
Elon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal.
Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty.
Dylan believes shares could react by December 8th.
|
| Claim this free stock pick before the December 8 deadline today |
|
Technology
|
|
|
Cloudflare (NYSE: NET) foreshadowed its October price plunge when price action hit new highs and MACD diverged. MACD divergence is a strong market signal, revealing a shifting balance that, in this case, was from bullish to bearish. The ensuing correction was sharp and severe, shaving more than 20%...
Read the Full Story
|
|
Markets
|
|
|
If you’re looking for proof that nobody on Wall Street has a crystal ball, look no further than Crocs (NASDAQ: CROX)—the maker of plastic-based foam clogs—which is outperforming every member of the Magnificent Seven this year. Of course, that may say more about Crocs’ more than 85% year-to-date (YT...
Read the Full Story
|
|
From Our Partners
|
|
|
Tobacco, telecom, pipelines, and healthcare real estate trade at 10 to 15 times earnings while the index yields about 1 percent.
A free report highlights seven cash-generating stocks with a 5 percent forward yield floor and roughly 6.5 percent average cash yield, capped at two picks per sector.
Each pick includes coverage numbers and an honest bear case. Five of the seven have raised payouts for 17 to 56 straight years.
|
| Get the seven high-yield dividend stocks free now |
|
Materials
|
|
|
Election headlines are dominating the tape, but the date that matters most for defense and critical minerals investors isn’t on any ballot. On Jan. 1, 2027, a Pentagon sourcing rule bars Chinese-origin rare earth metals and magnets from U.S. defense systems, and the support behind it runs across bo...
Read the Full Story
|
|
Technology
|
|
|
Atlassian’s (NASDAQ: TEAM) August earnings report was a standout performance for the company. CEO Mike Cannon-Brookes noted, “In the enterprise, we had an all-time record quarter at the $1 million level, the $3 million level and the $5 million level of deals. With our $3 million ARR customers growi...
Read the Full Story
|
|
Finance
|
|
|
Lemonade’s (NASDAQ: LMND) Q3 results reflect an accelerating growth story on the cusp of a major inflection. That is, from a cash-burning start-up insurance company, still reporting GAAP losses, to one approaching profitability, and the inflection is at hand. With the forecast to produce its first ...
Read the Full Story
|
|
Technology
|
|
|
Investors hit AI stocks extremely hard on Nov. 5, resulting in a sea of red for names across the industry. Markets didn't spare chip giant Broadcom (NASDAQ: AVGO); shares fell 10.4%, its largest single-day decline in five months. Despite this dramatic sell-off, a key regulatory filing has favorable...
Read the Full Story
|
|
Markets
|
|
|
Democratic victories across the country in the 2026 midterm elections could complicate approval of the Trump administration's proposed $1.5 trillion fiscal 2027 defense budget. In the immediate aftermath of the election, defense contractors like Lockheed Martin Corp. (NYSE: LMT) shed value, though ...
Read the Full Story
|
|
Tuesday's Early Bird Stock Of The Day
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment o...
|
Should I Buy AbbVie Stock? ABBV Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of AbbVie was last updated on Tuesday, November 10, 2026 at 1:05 AM.
AbbVie Bull Case
- AbbVie Inc. recently reported third-quarter earnings that exceeded expectations, with revenue of $17.40 billion and an EPS of $3.82, beating the consensus estimate of $3.73. This performance, combined with a raised full-year adjusted earnings outlook, strengthens the growth case for the stock and demonstrates the company's ability to sustain revenue growth of 10.3% year-over-year.
- The company recently increased its quarterly dividend to $1.82, representing an annualized yield of approximately 2.5% based on recent pricing. This move signals management's confidence in cash flow generation and provides a steady income stream for investors, which is particularly attractive given the stock's defensive characteristics in the healthcare sector.
- Wall Street analysts have shown increasing optimism, with Wells Fargo raising its price target to $340.00 and Piper Sandler to $303.00 in recent months. The consensus rating remains a "Moderate Buy," and the average price target of $297.46 suggests that the current stock price of $292.87 still offers modest upside potential relative to analyst expectations.
- AbbVie Inc. is expanding its pipeline and research capabilities, including a global licensing deal with Nxera Pharma for an EP4 receptor agonist targeting inflammatory bowel disease and the establishment of a new research facility in Oxford, UK. These moves indicate a strategic focus on diversifying growth beyond its legacy products and investing in future therapeutic areas such as immunology and neuroscience.
- Institutional investor interest remains strong, with 70.23% of the stock owned by institutional investors and hedge funds. Recent filings show that funds like Allspring Global Investments Holdings LLC and Cullinan Associates Inc. increased their positions in the third quarter, suggesting that large capital allocators continue to view AbbVie Inc. as a core holding in their portfolios.
AbbVie Bear Case
- The stock is trading near its 52-week high of $302.93, with the current price at $292.87. This proximity to recent peaks leaves limited room for further short-term appreciation and increases the risk of a pullback if the market sentiment shifts or if the company fails to meet the high expectations set by its recent earnings beat.
- AbbVie Inc. has a high dividend payout ratio of 119.10%, meaning the company is paying out more in dividends than it is earning in net income. While this provides a high yield, it may limit the company's ability to reinvest in research and development or absorb financial shocks, raising concerns about the sustainability of the dividend over the long term.
- Insider selling activity has been notable, with EVP Nicholas Donoghoe selling 32,710 shares in August 2026 and other executives like Perry C. Siatis and David Ryan Purdue also reducing their holdings in early 2026. Such sales can be interpreted as a lack of confidence from company insiders in the stock's near-term performance or a desire to diversify personal wealth.
- The company faces ongoing challenges related to the decline of its legacy product, Humira, which requires continuous demonstration that newer products like Skyrizi and Rinvoq can sustain growth. Investors must remain vigilant about the durability of these newer growth drivers, as any stumble in their adoption or performance could negatively impact the company's overall trajectory.
- Short interest in AbbVie Inc. remains significant, with approximately 15.58 million shares shorted as of the latest record date. Although short interest has decreased slightly month-over-month, the level of shorting indicates that a portion of the market remains skeptical about the stock's valuation or future performance, which could lead to volatility if these shorts are covered or if negative news emerges.
|
| View Today's Stock Pick |
|
|
|
0 Response to "🐤 Want to Escape the AI Sell-Off? This ETF Offers a Surprising Alternative"
Post a Comment